Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

Clinical trial NCT04704921 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04704921
Sponsor: AbbVie
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

AMD nAMD Wet Age-related Macular Degeneration wAMD Wet AMD CNV Neovascular AMD Neovascular Age-related Macular Degeneration Choroidal Neovascularization

Start date: 2020-12-29
Primary completion: 2026-12-01
Enrollment: 671

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.